Enroll the first patient in the OLYMPIA Phase 2 study of OC-01 in NK
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 18 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Enrollment of the first patient in the OLYMPIA Phase 2 study of OC-01 (varenicline) nasal spray in NK remains on track, planned for the first half of 2021.”
What we found
Evidence strength A What the grades mean
Later filings state the company announced enrollment of the first subject in the OLYMPIA Phase 2 trial in June 2021, before the first-half 2021 deadline.
-
A Oyster Point Pharma, Inc. 10-Q filed 2021-08-05
“In June 2021, the Company announced enrollment of the first subject in the OLYMPIA Phase 2 clinical trial of OC-01 (varenicline) nasal spray for the treatment of Stage 1 Neurotrophic Keratopathy (NK).” ✓ confirmed on the page
-
A Oyster Point Pharma, Inc. 10-K filed 2022-02-24
“In June 2021, the Company enrolled its first subject in the OLYMPIA Phase 2 clinical trial of OC-01 (varenicline solution) nasal spray for the treatment of Stage 1 Neurotrophic Keratopathy (NK).” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Enroll
- Deliverable
- First patient enrolled in OLYMPIA Phase 2 study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Oyster Point Pharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C720725-024117 · Corrections policy